Uses of monoclonial antibody 8H9
This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light chain CDR3 comprises QNGHSFPLT. In another embodiment, there is provided a polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the polypeptide comprises NYDIN, WIFPGDGSTQY, QTTATWFAY, RASQSISDYLH, YASQSIS, and QNGHSFPLT.
1. An isolated antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the isolated antibody comprises SEQ ID NOs:29-34, and the isolated antibody comprises sequences of human origin.
2. The antibody of claim 1 , wherein the antibody is a scFv.
3. The antibody of claim 1 , wherein the antibody is labelled.
4. The antibody of claim 1 , wherein the antibody is directly or indirectly coupled to a cytotoxic agent.
5. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
6. An isolated polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the isolated polypeptide comprises SEQ ID NOs:29-34 and sequences of human origin.
7. The polypeptide of claim 6 , wherein the polypeptide is a scFv.
8. The polypeptide of claim 6 , wherein the polypeptide is labelled.
9. The polypeptide of claim 6 , wherein the polypeptide is directly or indirectly coupled to a cytotoxic agent.
10. A composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier.